Treatment of Non-Infectious Uveitis Macular Edema Using Two Doses of Triamcinolone Acetonide: Comparative Study

To compare the efficacy and safety of two doses of intravitreal triamcinolone acetonide (2 mg and 4 mg) in treating non-infectious uveitic macular edema.

This prospective, randomized study assigned patients to Group A (4 mg; 0.1 mL) or B (2 mg; 0.05 mL) of intravitreal triamcinolone acetonide. Participants were assessed at 7, 30, 60, and 90 days post-procedure. Central retinal thickness (CRT), best-corrected visual acuity (BCVA), recurrence rate, adverse events (intraocular pressure [IOP] and cataract), and quality-of-life assessment (VFQ-NEI) were analyzed.

Thirty-two eyes (16 per group) completed the 3-month follow-up. Group A demonstrated a significantly greater reduction in CRT at the end of follow-up (p = 0.026). Group B had higher recurrence rates (Group A: Four [25%] eyes vs. Group B: eight [50%] eyes; [p = 0.137]). Although both groups showed transient IOP spike at 7 days post-procedure, no cases of intraocular hypertension were noticed at the end of the study. BCVA outcomes were comparable between groups (p = 0.192). The quality-of-life assessment questionnaire revealed significant improvement in near vision (p = 0.031) and mental health (p = 0.021) subscales in Group A.

Group A (4 mg) showed better clinical results in terms of anatomic outcomes, recurrence rates, and quality of life measures compared to Group B (2 mg). Although an IOP spike occurred in both groups 1 week post-procedure, no intraocular hypertension was observed 90 days post-procedure. Visual acuity outcomes were comparable between both groups at the end of the follow-up.